SkinTE by RegenETP for Diabetic Foot Ulcers: Likelihood of Approval

SkinTE is under clinical development by RegenETP and currently in Phase III for Diabetic Foot Ulcers.

Solid Phase II Trial Progress with Over 50% Patient Recruitment – Biotech Investments

Issuer: Berlin Cures Holding AG / Key word(s): Study 04.03.2024 / 12:00 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin

March 5, 2024

Virtual voice technology enhances follow-up care for TAVI patients

Clinical follow-up using virtual voice technology helped identify complications after transcatheter aortic valve implantation (TAVI) with a high degree of patient satisfaction, according to research

August 27, 2024

Comprehensive mental health coverage laws improve children’s access to care, study reveals

When states require insurers to cover mental and behavioral health, children get better access to care, according to a UC San Francisco-led study of nearly

August 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.